2025

• Chung, J. *, Vallurupalli, M.*, Noel, S., Schor, G., Liu, Y., Nobrega, C., Perera, J. J., Wrona, E., Hu, M., Lin, Y., Wu, D. W., Saberi, M., Scapozza, I., Cruickshank, A., Woods, E. C., Chuong, C. L., Birocchi, F., Kammula, A. V., Avila, O. I., Kocak, M., Doench, J. G., Procter, D., Thornton, L., Brunner, A. M., Winer, E., DeAngelo, D. J., Garcia, J. S., Stone, R. M., Jenkins, R. W., Maus, M. V., Graubert, T. A., Yates, K. B., Golub, T. R.†, & Manguso, R. T.† (2025). Sialylated CD43 is a glyco-immune checkpoint for macrophage phagocytosis. bioRxiv. 2025.05.05.652090.
• Fu C.*, Saddawi-Konefka R., Chinai J.M., Kim S.Y., Kammula A.V., Perera J.J., Jiang A., Tiwari P., Kistler E.N., Tang S., Luna S.M., Colvin K.J., Dubrot J., Anderson S., Fetterman R.A., Chuong C.L., Lane-Reticker S.K., Cheruiyot K., Muscato A.J., Alipour Z., Adkins D.R., Griffin G.K., Bernstein B.E., Egloff A.M., Yates K.B., Chernock R.D., Gutkind J.S., Uppaluri R., Manguso R.T. (2025) In vivo CRISPR screening in head and neck cancer reveals Uchl5 as an immunotherapy target. Nature Communications 16, 8572 
• Xie H*, Jiang A, Dey A, Dean JW, Perera JJ, Smith NP, Chen ACY, Anderson S, Cicerchia AM, Sun Y, Michaud WA, Florentin M, Fang J, Revach OY, Sharova T, Lawless A, Xu KH, Song Y, Patel B, Stevens JD, Lane WJ, Keskin DB, Cohen S, Lawrence DP, Sullivan RJ, Flaherty KT, Boland GM, Nieman LT, Sade-Feldman M, Hacohen N, Sen DR, Wu C, Gastman B, Qi R, Yin H, Villani AC, Manguso RT, Jenkins RW. “Lymphotoxin-driven cancer cell eradication by tumoricidal CD8+ tumor-infiltrating lymphocytes.” bioRxiv 025.11.19.689204

2024

• Tsao, H. W.*, Anderson, S.*, Finn, K. J.*, Perera, J. J., Pass, L. F., Schneider, E. M., Jiang, A., Fetterman, R., Chuong, C. L., Kozuma, K., Stickler, M. M., Creixell, M., Klaeger, S., Phulphagar, K. M., Rachimi, S., Verzani, E. K., Olsson, N., Dubrot, J., Pech, M. F., Silkworth, W., Harding, F.†, Yates, K.B.†, Manguso, R. T.† (2024). Targeting the aminopeptidase ERAP enhances antitumor immunity by disrupting the NKG2A-HLA-E inhibitory checkpoint. Immunity, 57(12), 2863–2878.e12. PMID: 39561763

2022

• Al-Kharboosh, R*., Perera, J. J.*, Bechtle, A., Bu, G., & Quinones-Hinojosa, A. (2022). Emerging point-of-care autologous cellular therapy using adipose-derived stromal vascular fraction for neurodegenerative diseases. Clinical and Translational Medicine, 12(12), e1093. PMCID: PMC9736801
• Tomaszewski, W. H.*, Waibl-Polania, J., Chakraborty, M., Perera, J., Ratiu, J., Miggelbrink, A., McDonnell, D. P., Khasraw, M., Ashley, D. M., Fecci, P. E., Racioppi, L., Sanchez-Perez, L., Gunn, M. D., & Sampson, J. H.† (2022). Neuronal CaMKK2 promotes immunosuppression and checkpoint blockade resistance in glioblastoma. Nature Communications, 13(1), 6483. PMCID: PMC9617949

* denotes co-first authors.

† denotes co-corresponding authors.